Guduchi Tinospora cordifolia (Willd.) Hook.f. & Thomson
Also called: giloy, Menispermum cordifolium (synonym)
Guduchi (giloy) is a climbing shrub native to India and South Asia used in Ayurveda and widely taken in India during the COVID-19 pandemic. LiverTox rates it a well-established cause of liver injury, with more than 50 published cases since 2017.
- Category
- Botanical
- Part used
- Leaf, root, bark and stem preparations and extracts
- Strongest evidence
- C Limited
- Native range
- Native from the Indian Subcontinent to Indo-China (POWO)
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. No review stating a count was found. This entry cites 3 RCTs of guduchi (Tinospora cordifolia) alone: an 8-week placebo-controlled trial in 75 patients and two trials adding it to standard care (50 and 30 patients), 1993-2007. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CLungs and airways1 topic
DImmune system and infection1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Allergic rhinitis | C | One 8-week placebo-controlled trial in 75 patients reported more relief of sneezing, nasal discharge, obstruction and itching with a T. cordifolia extract. [2] |
| Claimed immune and other effects | D | LiverTox states that none of the biologic or clinical activities claimed from animal studies has been shown in humans. [1] |
Main constituents: More than 60 compounds: lactones, steroids, flavonoids, lignans, alkaloids and di- and monoterpenes, including characteristic clerodane-type furanoditerpenoids [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- LiverTox: the typical dose is 400 to 1000 mg daily. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score AABCDEA: well known causeE: unlikely cause
LiverTox likelihood score A (well-established cause of clinically apparent liver injury) …
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Liver injury: more than 50 cases of clinically apparent acute liver injury reported since 2017, mostly from India and Thailand; usually hepatocellular, with ALT and AST often 10 to 50 times the upper limit of normal. [1]
- Several fatal cases with submassive hepatic necrosis were described, mostly in people with preexisting liver disease. LiverTox likelihood score A (well-established cause); injury appears immunologically mediated and is usually self-limited. [1]
- In a 2021 series of six patients (median 90 days of use), guduchi was linked to autoimmune-like hepatitis; four had silent chronic liver disease. Authors advise caution, especially in people predisposed to autoimmune disorders. [3]
- Short, small clinical studies described side effects as uncommon and minimal, without mention of liver toxicity. [1]
Identity, quality and standardization
- Tinospora crispa, a similar-looking species, has also been linked to liver injury; in one case series, morphology, microscopy, HPTLC and DNA barcoding confirmed the plant samples were T. cordifolia. [4]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Clerodane-type furanoditerpenoids (a diterpenoid is suspected in liver injury; the responsible chemical is unknown) Terpenoids (diterpenoids) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming Tinospora cordifolia, each as one ingredient of a multi-ingredient combination (earliest NDI 193 submitted 2003-01-21; most recent NDI 810 submitted 2013-10-21). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of guduchi (Tinospora cordifolia) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- LiverTox likelihood score A (well-established cause of clinically apparent liver injury); more than 50 cases since 2017, several fatal, mostly in people with preexisting liver disease (chapter updated June 27, 2025). [P1]
- A 2021 case series described autoimmune-like hepatitis or unmasking of underlying autoimmune liver disease; median time to resolution after stopping was 86.5 days. [P4]
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Confusion with Tinospora crispa (also linked to liver injury) was raised for Indian liver-injury cases; HPTLC, DNA barcoding and microscopy confirmed T. cordifolia, while two commercial products could not be analyzed. [P5]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P6]
- Species identity versus Tinospora crispa (morphology, microscopy, HPTLC, DNA barcoding) — The two species look alike and both have been implicated in liver injury. [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- NIH LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tinospora (last update June 27, 2025), 2025-06-27. ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- Nagral A, et al. Herbal immune booster-induced liver injury in the COVID-19 pandemic - a case series. J Clin Exp Hepatol 2021;11(6):732-738 (PMID 34230786), 2021-11. pubmed.ncbi.nlm.nih.gov
- Nagral A, et al. Herb-induced liver injury - a guide to approach. Lessons from the Tinospora cordifolia (giloy) case series story. J Clin Exp Hepatol 2023;13(2):360-371 (PMID 36950495), 2023-03. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
Sources
- NIH LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tinospora (last update June 27, 2025), 2025-06-27. ncbi.nlm.nih.gov
- Badar VA, et al. Efficacy of Tinospora cordifolia in allergic rhinitis. J Ethnopharmacol 2005;96(3):445-449 (PMID 15619563), 2005-01-15. pubmed.ncbi.nlm.nih.gov
- Nagral A, et al. Herbal immune booster-induced liver injury in the COVID-19 pandemic - a case series. J Clin Exp Hepatol 2021;11(6):732-738 (PMID 34230786), 2021-11. pubmed.ncbi.nlm.nih.gov
- Nagral A, et al. Herb-induced liver injury - a guide to approach. Lessons from the Tinospora cordifolia (giloy) case series story. J Clin Exp Hepatol 2023;13(2):360-371 (PMID 36950495), 2023-03. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Tinospora cordifolia (Willd.) Hook.f. & Thomson (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- Purandare H, et al. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study. Indian J Med Sci 2007;61(6):347-55 (PMID 17558098), 2007-06. pubmed.ncbi.nlm.nih.gov
- Rege N, et al. Immunotherapy with Tinospora cordifolia: a new lead in the management of obstructive jaundice. Indian J Gastroenterol 1993;12(1):5-8 (PMID 8330924), 1993-01. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.